Tumor mutation burden is an emerging biomarker to predict sensitivity to immune checkpoint inhibitors and has been demonstrated to be associated with response to anti‐PD‐1/PD‐L1 immunotherapy.41 In this study, we performed a TMB comparison in our cohort vs other NPC cohorts and found that only minor differences in TMB existed among the cohorts. This evidence concerns the gene CD274 and nasopharyngeal carcinoma.